| ABBV | AbbVie Inc. | ApprovalH2 2026FDA decision SKYRIZI subcutaneous induction in Crohn's disease expected later in 2026 | 3 | View Stock ↗ |
| ACAD | ACADIA Pharmaceuticals Inc. | Trial resultsH2 2026Remlifanserin Ph2 RADIANT ADP topline narrowed to Sept–Oct 2026 | 3 | View Stock ↗ |
| ALKS | Alkermes plc | Trial resultsQ4 2026Vibrance-3 Phase 2 completion in idiopathic hypersomnia | 3 | View Stock ↗ |
| ALNY | Alnylam Pharmaceuticals, Inc. | Trial resultsH2 2026ALN-2232 Phase 1 obesity data | 3 | View Stock ↗ |
| AMGN | Amgen Inc. | Milestone2026Three MariTide Phase 3 studies in type 2 diabetes to start in 2026 | 6 | View Stock ↗ |
| ARGX | argenx SE | Milestone2026Adimanebart (ARGX-119) registrational study start in congenital myasthenic syndromes | 9 | View Stock ↗ |
| ARWR | Arrowhead Pharmaceuticals, Inc. | MilestoneH2 2026sNDA submission to FDA for plozasiran in severe hypertriglyceridemia | 5 | View Stock ↗ |
| AXSM | Axsome Therapeutics, Inc. | Trial resultsQ4 2026ENGAGE Phase 3 topline: solriamfetol in binge eating disorder | 3 | View Stock ↗ |
| AZN | AstraZeneca PLC | FDA decisionH2 2026Extended FDA decision window for camizestrant (SERENA-6) | 5 | View Stock ↗ |
| BEAM | Beam Therapeutics Inc. | Trial resultsH2 2026Updated BEACON Phase 1/2 data for risto-cel by year-end 2026 | 3 | View Stock ↗ |
| BIIB | Biogen Inc. | ConferenceH2 2026Litifilimab AMETHYST 52-week Phase 2 CLE data at EADV 2026 | 4 | View Stock ↗ |
| BMRN | BioMarin Pharmaceutical Inc. | MilestoneQ4 2026BMN 351 DMD program update by year-end 2026 | 4 | View Stock ↗ |
| BMY | Bristol-Myers Squibb Company | Trial resultsH2 2026Phase 3 LIBREXIA-STROKE topline for milvexian (with J&J) | 6 | View Stock ↗ |
| BNTX | BioNTech SE | Trial results2026Multiple pumitamig combination data readouts expected in 2026 | 5 | View Stock ↗ |
| CRSP | CRISPR Therapeutics AG | Trial results2026Lp(a) program (CTX320/CTX321) update expected in 2026 | 4 | View Stock ↗ |
| CYTK | Cytokinetics, Incorporated | MilestoneH2 2026AMBER-HFpEF Cohort 1 ulacamten enrollment completion | 3 | View Stock ↗ |
| DNLI | Denali Therapeutics Inc. | Trial resultsH2 2026DNL593 Phase 1/2 results in FTD-GRN | 7 | View Stock ↗ |
| EXEL | Exelixis, Inc. | Trial resultsH2 2026STELLAR-304 Phase 3 topline in non-clear cell RCC | 3 | View Stock ↗ |
| GERN | Geron Corporation | Trial resultsH2 2026IMpactMF Phase 3 interim analysis (overall survival) in relapsed/refractory myelofibrosis | 1 | View Stock ↗ |
| GILD | Gilead Sciences, Inc. | Trial resultsH2 2026Trodelvy Phase 3 ASCENT-GYN update in advanced/recurrent endometrial cancer | 8 | View Stock ↗ |
| GSK | GSK plc | MilestoneH2 2026Camlipixant US regulatory submission planned for H2 2026 | 14 | View Stock ↗ |
| HALO | Halozyme Therapeutics, Inc. | ApprovalQ1 2027FDA decision on RYBREVANT FASPRO (ENHANZE) sBLA in head and neck cancer (partner: J&J) | 2 | View Stock ↗ |
| IMVT | Immunovant, Inc. | Trial resultsH2 2026IMVT-1402 proof-of-concept topline in cutaneous lupus (CLE) | 3 | View Stock ↗ |
| INCY | Incyte Corporation | Trial resultsH2 2026Niktimvo + ruxolitinib data in newly diagnosed chronic GVHD | 12 | View Stock ↗ |
| INSM | Insmed Incorporated | ApprovalH2 2026Japan regulatory decision on brensocatib in bronchiectasis | 4 | View Stock ↗ |
| IONS | Ionis Pharmaceuticals, Inc. | Trial resultsH2 2026HORIZON Phase 3 Lp(a) cardiovascular outcomes results for pelacarsen | 3 | View Stock ↗ |
| IOVA | Iovance Biotherapeutics, Inc. | ApprovalH2 2026Potential UK (MHRA) approval of Amtagvi in advanced melanoma | 7 | View Stock ↗ |
| JAZZ | Jazz Pharmaceuticals plc | Trial resultsH1 2027Modeyso ACTION Phase 3 interim OS analysis | 1 | View Stock ↗ |
| JNJ | Johnson & Johnson | FDA decisionH2 2026FDA decision window for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia | 6 | View Stock ↗ |
| KRYS | Krystal Biotech, Inc. | Trial resultsH2 2026KB407 interim results in cystic fibrosis | 11 | View Stock ↗ |
| KYMR | Kymera Therapeutics, Inc. | Trial resultsQ4 2026KT-621 BROADEN2 Phase 2b topline data in atopic dermatitis | 5 | View Stock ↗ |
| LEGN | Legend Biotech Corporation | MilestoneH2 2026Legend targets multiple IND filings (oncology, autoimmune) starting 2H 2026 | 2 | View Stock ↗ |
| LLY | Eli Lilly and Company | FDA decisionH2 2026FDA decision on tirzepatide MACE-reduction indication (SURPASS-CVOT) | 2 | View Stock ↗ |
| MDGL | Madrigal Pharmaceuticals, Inc. | MilestoneQ4 2026Ervogastat/resmetirom drug-drug interaction study start | 2 | View Stock ↗ |
| MRK | Merck & Co., Inc. | Trial resultsH2 2026Sac-TMT TroFuse-005 endometrial cancer detailed Ph3 data presentation | 1 | View Stock ↗ |
| MRNA | Moderna, Inc. | Approval2026mRNA-1010 (mFLUSIVA) ex-US approvals (EU/Canada/Australia) expected to begin | 2 | View Stock ↗ |
| NBIX | Neurocrine Biosciences, Inc. | Trial resultsH2 2027Phase 3 topline data for osavampator in major depressive disorder | 2 | View Stock ↗ |
| NTLA | Intellia Therapeutics, Inc. | MilestoneH2 2026Lonvo-z BLA submission and anticipated FDA acceptance in hereditary angioedema | 3 | View Stock ↗ |
| NVAX | Novavax, Inc. | MilestoneH1 2027Nuvaxovid manufacturing tech transfer to Sanofi completion ($75M milestone) | 2 | View Stock ↗ |
| NVO | Novo Nordisk A/S | MilestoneH2 2026Phase 3 starts: oral zenagamtide (Q3), SC zenagamtide CVOT and high-dose cagrilintide (Q4) | 9 | View Stock ↗ |
| NVS | Novartis AG | Trial resultsH2 2026Phase 3 Lp(a) HORIZON topline for pelacarsen | 19 | View Stock ↗ |
| PCVX | Vaxcyte, Inc. | Trial resultsQ4 2026OPUS-1 Phase 3 pivotal topline for VAX-31 in adults | 3 | View Stock ↗ |
| PFE | Pfizer Inc. | Trial results2026Mevrometostat MEVPRO-1 Ph3 mCRPC readout | 6 | View Stock ↗ |
| PTCT | PTC Therapeutics, Inc. | MilestoneH2 2026FDA engagement on votoplam PIVOT-HD 24-month results in Huntington's disease | 2 | View Stock ↗ |
| RARE | Ultragenyx Pharmaceutical Inc. | Trial resultsH2 2026GTX-102 Phase 3 Aspire Angelman topline now guided to Sept/Oct 2026 | 5 | View Stock ↗ |
| REGN | Regeneron Pharmaceuticals, Inc. | FDA decisionNov 2026PDUFA target action date for cemdisiran in generalized myasthenia gravis | 2 | View Stock ↗ |
| RXRX | Recursion Pharmaceuticals, Inc. | MilestoneH2 2026REC-4881 FDA registrational-path update in FAP | 7 | View Stock ↗ |
| RYTM | Rhythm Pharmaceuticals, Inc. | MilestoneH2 2026Setmelanotide congenital HO substudy enrollment completion | 4 | View Stock ↗ |
| SMMT | Summit Therapeutics Inc. | Trial resultsH2 2026HARMONi-3 squamous cohort final PFS analysis | 3 | View Stock ↗ |
| SNY | Sanofi | Trial resultsH2 2026Sarclisa Phase 3 data in transplant-eligible multiple myeloma | 16 | View Stock ↗ |
| SRPT | Sarepta Therapeutics, Inc. | Trial resultsH2 2026Phase 1/2 MAD-cohort readouts for siRNA programs in DM1 and FSHD | 4 | View Stock ↗ |
| TAK | Takeda Pharmaceutical Company Limited | Milestone2026Zasocitinib regulatory submissions in plaque psoriasis (US NDA and other authorities) | 3 | View Stock ↗ |
| TGTX | TG Therapeutics, Inc. | ConferenceH2 2026Full Phase 3 ENHANCE trial results presentation (IV BRIUMVI rapid dosing) | 3 | View Stock ↗ |
| UTHR | United Therapeutics Corporation | MilestoneH2 2026Ralinepag NDA submission for PAH | 5 | View Stock ↗ |
| VKTX | Viking Therapeutics, Inc. | MilestoneQ4 2026Initiation of Phase 3 program for oral VK2735 | 2 | View Stock ↗ |
| VRTX | Vertex Pharmaceuticals Incorporated | Trial resultsH2 2026Inaxaplin Phase 2 AMPLIFIED data in AMKD (fall 2026) | 8 | View Stock ↗ |